CSat Investment Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CSat Investment Advisory’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,984	Closed	-$154K	–	1085
2020 Q3	$154K	Sell	1,984 -1,754	-47%	-$121K	0.01%	328
2020 Q2	$208K	Buy	3,738 +3,349	+861%	+$143K	0.03%	306
2020 Q1	$12K	Buy	389 +69	+22%	+$2.33K	﹤0.01%	879
2019 Q4	$12K	Buy	320 +40	+14%	+$1.23K	﹤0.01%	952
2019 Q3	$8K	Buy	280 +40	+17%	+$1.03K	﹤0.01%	996
2019 Q2	$6K	Buy	+240	New	+$6.09K	﹤0.01%	1041

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CSat Investment Advisory's HZNP Position: Q4 2020 in Review

CSat Investment Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 1,984 shares — an estimated $154K sold.

CSat Investment Advisory first reported a position in HZNP in Q2 2019 and held it in 6 quarters. The position peaked at $208K in Q2 2020. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

CSat Investment Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
CSat Investment Advisory sold 1,984 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $154K.
CSat Investment Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 6 quarters.
CSat Investment Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $208K in Q2 2020.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.